Showing results (781-790 of 2,229) with videos related to
Sort By:
Pageof 223
Cancer Biotherapy & Radiopharmaceuticals|July 2, 2005
Significant tumor regression induced by microencapsulation of recombinant tumor cells secreting fusion proteinMeiqing Shi, Siguo Hao, Mabood Quereshi, et al.Cancer Biotherapy & Radiopharmaceuticals|July 2, 2005
Biodistribution and imaging of FDG in rats with LS174T carcinoma xenografts and focal Escherichia coli infectionPeter J M Kok, Juliëtte E M van Eerd, Otto C Boerman, et al.Cancer Biotherapy & Radiopharmaceuticals|January 15, 2005
Phase I clinical trial of targeted therapy using 131I-Hepama-1 mAb in patients with hepatocellular carcinomaShaoliang Chen, Beilei Li, Hong Xie, et al.Cancer Biotherapy & Radiopharmaceuticals|January 15, 2005
Efficacy of 99mTc-EDDA/HYNIC-TOC scintigraphy in differential diagnosis of solitary pulmonary nodulesAnna Płachcińska, Renata Mikołajczak, Helmut Maecke, et al.Cancer Biotherapy & Radiopharmaceuticals|September 30, 2004
Improved tumor targeting of radiolabeled RGD peptides using rapid dose fractionationMarcel Janssen, Cathelijne Frielink, Ingrid Dijkgraaf, et al.Cancer Biotherapy & Radiopharmaceuticals|September 30, 2004
Pharmacokinetics and tumor targeting of 131I-labeled F(ab')2 fragments of the chimeric monoclonal antibody G250: preclinical and clinical pilot studiesAdrienne Brouwers, Peter Mulders, Egbert Oosterwijk, et al.Cancer Biotherapy & Radiopharmaceuticals|September 30, 2004
Quantitative imaging of yttrium-86 PET with the ECAT EXACT HR+ in 2D modeThomas Kull, Jochen Ruckgaber, Rolf Weller, et al.Cancer Biotherapy & Radiopharmaceuticals|August 3, 2004
Use of the linear-quadratic radiobiological model for quantifying kidney response in targeted radiotherapyRoger DaleCancer Biotherapy & Radiopharmaceuticals|March 22, 2005
The LundADose method for planar image activity quantification and absorbed-dose assessment in radionuclide therapyKatarina Sjögreen, Michael Ljungberg, Karin Wingårdh, et al.Cancer Biotherapy & Radiopharmaceuticals|February 27, 2008
Low-dose cyclophosphamide and continuous-infusion interleukin-2 with famotidine in previously treated metastatic melanoma or kidney cancerWalter D Y Quan, Francine M Quan, Linda A King, et al.Pageof 223